{"classes":[{"categories":[{"measurements":[{"comment":"NA indicates that the median, lower and upper limit of confidence interval (CI) was not estimable due to insufficient number of events to determine this value.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA indicates that the upper limit of CI was not estimable due to insufficient number of events to determine this value.","groupId":"OG001","lowerLimit":"5.9","upperLimit":"NA","value":"20.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"DOR was defined for participants with a confirmed response (PR or better) as the duration from the date of initial documentation of a response (PR or better) according to the IMWG criteria to the date of first documented evidence of progressive disease according to the IMWG criteria or death due to progressive disease. PR:\\>=50% reduction of serum M-protein and reduction in 24hours urinary M-protein by \\>=90% or to \\<200 mg/24hours. If serum and urine M-protein are unmeasurable, a \\>=50% decrease in difference involved and uninvolved FLC levels required in place of M-protein criteria. If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \\>=50% reduction in PCs is required in place of M-protein, provided baseline bone marrow PCs % was \\>=30%. In addition to the above criteria, if present at baseline, a \\>=50% reduction in the size of soft tissue plasmacytomas is also required.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction therapy:Participants received daratumumab, cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) as: daratumumab 8 mg/kg IV on Cycle 1(Day 1,2) and 16 mg/kg IV on Cycle 1(Days 8,15,22), Cycle 2 (Days 1,8,15,22), Cycles 3-6 (Days 1,15), Cycles 7-8(Day 1); Cyclophosphamide 300 mg/m\\^2 orally on Days 1,8,15,22 of each cycle (28 days); Bortezomib 1.5 mg/m\\^2 SC on Days 1,8,15 of each cycle; Dexamethasone 20 mg IV on Cycle 1(Day1,2,8,15,22) and orally on Cycle 1(Day 9,16,23), 40 mg IV or oral on Cycle 2 (Days 1,8,15,22), Cycle 3-8 (\\[if with CyBorD\\] Days 1,8,15,22). Consolidation therapy (CT):Participants who were considered eligible for transplant underwent autologous stem cell transplantation \\[ASCT\\] at investigator discretion. Maintenance therapy:Daratumumab 16 mg/kg IV on Day 1 for 12 cycles or until PD, whichever occurred first; Dexamethasone 12 mg IV or oral on Day 1 of each cycle(for ASCT participants, maintenance therapy was to begin approximately 90 days after ASCT).","id":"OG000","title":"Newly Diagnosed Multiple Myeloma (NDMM)"},{"description":"Participants with RMM (defined as having achieved at least a PR with first-line therapy before progression) received treatment as-Induction therapy:Participants received Dara-CyBorD as: daratumumab 8 mg/kg IV on Cycle 1(Day 1,2) and 16 mg/kg IV on Cycle 1(Days 8,15,22),Cycle 2 (Days 1,8,15,22),Cycles 3-6(Days 1,15),Cycles 7-8(Day 1); Cyclophosphamide 300 mg/m\\^2 orally on Days 1,8,15,22 of each cycle (28 days); Bortezomib 1.5 mg/m\\^2 SC on Days 1,8,15 of each cycle; Dexamethasone 20 mg IV on Cycle 1(Day1,2,8,15,22) and orally on Cycle 1(Day 9,16,23), 40 mg IV or oral on Cycle 2(Days 1,8,15,22),Cycle 3-8 (\\[if with CyBorD\\] Days 1,8,15,22). CT: Participants who were considered eligible for transplant underwent ASCT at investigator discretion. Maintenance therapy:Daratumumab 16 mg/kg IV on Day 1 for 12 cycles or until PD, whichever occurred first; Dexamethasone 12 mg IV or oral on Day 1 of each cycle(for ASCT participants, maintenance therapy was to begin approximately 90 days after ASCT).","id":"OG001","title":"Relapsed Multiple Myeloma (RMM)"}],"paramType":"MEDIAN","populationDescription":"Population included responders (PR or better) in response-evaluable set.","reportingStatus":"POSTED","timeFrame":"Up to 36 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}